OBJECTIVE To investigate the availability of CYP450-2D6 [CYP2D6) genotyping results in general practitioner (GP1 and/or community pharmacy records, and the influence thereof on psychotropic CYP2D6 substrate dosing. DESIGN A retrospective survey with cross-sectional analysis. METHODS Primary outcome was the percentage of patients genotyped for CYP2D6 with their genotype/phenotype registered in GP and/or pharmacy records. Secondary outcome was the number of defined daily doses of psychotropic CYP2D6 substrates prescribed after genotyping. RESULTS For 216 out of 1307 eligible patients, medication overviews could be obtained. Genotyping results were available at GPS for 3.1% and at pharmacies for 5.9%. The average psychotropic CYP2D6 substrate dose was not different between any non-extensive metabolizer group and the extensive metabolizer group (all P ≥ 0.486). CONCLUSION Valuable information for individualizing psychiatric pharmacotherapy is lost on a large scale.
|Translated title of the contribution||Availability of CYP2D6 genotyping results in general practitioner and community pharmacy medical records|
|Number of pages||5|
|Publication status||Published - 27-Oct-2017|